The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
03 2019
Historique:
received: 04 09 2018
revised: 11 11 2018
accepted: 26 11 2018
pubmed: 12 12 2018
medline: 18 12 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

The natural history and molecular biology of oligometastatic prostate cancer differentiate it from polymetastatic disease. Clinically, oligometastatic disease is also predictive and prognostic for different outcomes. Studies specific to this population are required to establish the benefits of intervention.

Identifiants

pubmed: 30527643
pii: S2405-4569(18)30372-9
doi: 10.1016/j.euf.2018.11.011
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-118

Informations de copyright

Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Michael Jonathan Kucharczyk (MJ)

Jewish General Hospital, Montreal, Canada.

Gwenaelle Gravis (G)

Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France.

Tamim Niazi (T)

Jewish General Hospital, Montreal, Canada. Electronic address: tniazi@jgh.mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH